Thursday, January 19, 2017

Stats of the year: 2016 By the Numbers

A review of the 2016 statistics from the multiple facets that make up the healthcare arena includes: 

  • Television Commercials: A combined 1.3 million ads for prescription and over the counter drugs, raking in an estimated revenue of $4.6 million.
  • Opioid Deaths: A nearly 20% increase in overdose deaths in Massachusetts attributed to the synthetic opioid, fentanyl.
  • Expensive Drug Treatments: Only 3% of Kentucky Medicaid participants were able to receive hepatitis C treatments – a sign of the epidemic burdening the Medicaid system nationwide.
  • Growth in Biotech: Private biotech companies received nearly $4 billion less in venture capital investment than in 2015.


 Additional topics include the gene editing technology, CRISPR; stem cell treatment facilities; the impact of Zika on birth rates in Columbia; and hospice care utilization.

Read STAT News' article on it here.

Friday, December 30, 2016

Study: Patients Cared For by Female Doctors Fare Better Than Those Treated by Men

A new study, published in Journal of the American Medical Association (JAMA) International, reports that Medicare patients over the age of 80 were less likely to die or be readmitted within 30 days if they were treated by a female doctor; estimates based on the findings indicate that as many as 32,000 annual deaths may have been avoided if the provider had been female. While the study does not draw conclusions regarding why this is the case, anecdotally, experts hypothesize that females are generally better communicators and have higher levels of emotional intelligence. These skills play an important role in not only working with patients, but also when working with the nurses who arrange discharge, social work, home care, etc, and the family members who will play a large role in treatment after discharge.

Listen to the NPR podcast on it here.

Monday, December 12, 2016

Chicago Will License Pharma Sales Reps to Fight Opioid Overprescribing

Chicago will enact a new requirement that all pharmaceutical sales reps maintain a license based on their training for ethics, marketing regulations and industry laws; at a cost of $750, the reps will be responsible for applicable fees and annual renewals. The new ordinance also requires paperwork to be filed with the city regarding the reps’ activities and physician contact. The new regulations come after Chicago filed lawsuits against multiple drug manufacturers and their role in the current opioid epidemic. The fees are expected to exceed $1 million for the city, which will then be used to support ongoing education efforts, regulatory costs and expanding treatment availability for addicts. The pharmaceutical industry argues that the new requirements do nothing to curb opioid abuse.

Read a Stat News article on it here.

Tuesday, December 6, 2016

Should We Use Canada and The WHO's 'Essential Medicines' as Guides for US Drug Pricing?

Revamping our Nation’s approach to drug pricing will be a daunting task and is one that the public is expecting from our next president. Experts suggest a foundation be built from two main sources:

  1. The World Health Organization’s (WHO) Essential Medicines list: Containing over 445 medicines deemed as essential in satisfying the priority health care needs of a population, the Essential Medicines list could serve as a model for the U.S. in identifying important drugs that should be protected from price surges and available to the entire population.
  1. The Canadian approach to drug pricing includes a review of efficacy, quality and safety; the proposed price by the manufacturer; prices of competing medications; and prices set in other countries. Negotiations for drug prices include the pan-Canadian Pharmaceutical Alliance and a price is determined for all provinces of the country.
Read Stat News' article on it here.

Wednesday, November 23, 2016

[Podcast] A Powerful Duo Against HIV

Summary: Current treatment for HIV is a lifelong regimen of antiretroviral drugs that place significant economic and clinical stress on the patients being treated. Additionally, if individuals stop taking these drugs, the virus quickly multiplies and rebounds to its original levels. A major component in the weakening of the immune system by the virus occurs through the destruction of immune cells in the gut. The virus targets these cells, forcing the body to work continuously to repair the damage and, subsequently, pulling needed resources from the rest of the immune system. Researchers have developed a therapy to destroy the protein attached to the cells that directs them to the gut and allows the body to mount a system-wide immune response during infection. When used after a course of antiretrovirals, monkeys receiving the new therapy have been able to control the infection without additional treatments for two years. A safety study for use in humans is currently underway.

You can hear the podcast here.

Monday, October 31, 2016

A Cure for a Childhood Cancer - but Will It Last?

Article Summary: CAR-T, an experimental treatment for cancer that supercharges the patient’s immune system by genetically modifying immune cells, has had incredible results at high risks. However, the risks of the treatment include death, though many of them are seen as terminal without the treatment, and a new concern is that the cancer will return. It is unknown if the results of the treatment are permanent or if the cancer will return and, if it does, how quickly this will occur.

You can read MIT Technology Review's article on it here.